Overview


According to FutureWise analysis the market for triple-negative breast cancer treatment in 2023 is US$ 0.63 billion, and is expected to reach US$ 0.86 billion by 2031 at a CAGR of 3.9%.

Breast cancer that is classified as triple-negative lacks either estrogen or progesterone receptors (ER or PR), as well as making either too little or too much of the HER2 protein. (All three tests yield "negative" results for the cells.) These malignancies tend to affect women under the age of 40 who are Black or carry the BRCA1 mutation more frequently. Triple-negative breast cancer is considered aggressive cancer because it grows quickly and is more likely to have spread when discovered. TNBC is likely to reoccur after treatment than other types of breast cancer. The majority of triple-negative tumours are basal-like molecular subtypes of breast cancer, but the terms are not entirely synonymous. Around 10-15% of all breast tumours are triple-negative breast cancers (TNBC).

HER2 positive/oestrogen receptor (ER) negative subtype and the basal-like subtype are two hormone receptor-negative subtypes of breast cancer that have been identified through gene expression studies. The luminal subtypes, which typically express hormone receptor-related genes, are another major subtype of breast cancer. The prognosis of the subtypes varies, with the two-hormone receptor-negative categories typically having worse results than the luminal divisions. The prognostic environment for breast cancer may alter, though, as a result of advancements in chemotherapy, endocrine therapy, and HER2-targeted therapy. Chemotherapy is the backbone of treatment for triple-negative breast cancer because it is resistant to hormonal treatments like tamoxifen and aromatase inhibitors as well as HER2-targeted medications like trastuzumab. The interest in this group of patients has grown as a result of the absence of targeted medicines.

The market for triple-negative breast cancer is expected to expand due to an increase in breast cancer cases, increased demand for treatment options in private hospitals, increased private healthcare provider investments in healthcare infrastructure, increased medical tourism, and improved healthcare standards and practices. Companies in the global triple-negative breast cancer therapy market are likely to benefit from significant growth opportunities due to rising healthcare spending and demand for better disease diagnosis over the forecast period. Innovation has provided breast cancer patients a great deal of hope for the future because of increased research into novel therapy pathways and strategies to employ existing treatments more successfully alongside or after one another. This is also anticipated to increase demand for the treatment of triple-negative breast cancer. Throughout the projection period, the possibility of unfavourable reactions to breast cancer therapies such as targeted therapy is also anticipated to restrain market expansion. The market for treating triple-negative breast cancer may see new difficulties in the near future as a result of the challenging reimbursement structure and several patent expirations.

FutureWise Market Research has published a report that provides an insightful analysis of triple negative breast cancer market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the triple negative breast cancer market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • AstraZeneca PLC.
  • Pfizer, Inc.
  • F. Hoffman - La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Mylan N.V.
  • Eli Lilly and Company
  • Celgene Corporation
  • Sanofi S.A.
  • Johnson & Johnson Services, Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Type

  • Doxorubicin
  • Cyclophosphamide
  • Paclitaxel
  • Docetaxel 
  • Cisplatin/Carboplatin 
  • Others

By Distribution Channel 

  • Hospital Pharmacies
  • Specialty Cancer Clinics

By Region

  • Europe  
  • North America  
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. By region, North America is the highest revenue shareholding one, with 43.4%, due to improved healthcare systems and an increase in the number of foundations and independent venture firms that assist the biopharmaceutical industry. The market for HER-2 negative breast cancer is driven by the existence of prominent manufacturers across numerous states and the receipt of investment from numerous venture partners. For instance, the Organization for Economic Co-operation and Development (OECD) reported that in June 2022, healthcare spending in the United States accounted for 17.8% of the country's entire gross domestic product (GDP) in 2021. The population's access to technologically sophisticated medicines and systems to treat cases of HER-2 negative breast cancer is anticipated to increase with rising health spending, driving the market's expansion. Also, the expansion in the region is being driven by an increase in HER-2 negative breast cancer occurrences. For instance, the January 2022 update from breastcancer.org states that 1 in 8 women in the US (or roughly 13%) develop invasive breast cancer over their lifetime. These high breast cancer incidence rates will benefit the use of therapeutic options that support market expansion in the region. By end-user; hospitals are the largest segment with 66.4% share. Additionally, by treatment type; lumpectomy accounts for 44.2% share in global market in 2022.

  • Tier 1 players- established companies in the market with major market share
  • Tier 2 players
  • New Entrants
  • Emerging players which are growing rapidly
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data points affecting market growth
  • To provide with an exhaustive analysis on the Triple Negative Breast Cancer Market By Drug Type, By Distribution Channel, and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Triple Negative Breast Cancer Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Triple Negative Breast Cancer Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Triple Negative Breast Cancer Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Triple Negative Breast Cancer Treatment Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Doxorubicin
        2. Cyclophosphamide
        3. Paclitaxel
        4. Docetaxel
        5. Cisplatin/Carboplatin
        6. Others

  • 8.   Triple Negative Breast Cancer Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Specialty Cancer Clinics

  • 9.   North America Triple Negative Breast Cancer Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Triple Negative Breast Cancer Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Triple Negative Breast Cancer Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
            2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Triple Negative Breast Cancer Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AstraZeneca PLC
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pfizer, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. F. Hoffman - La Roche Ltd.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bristol-Myers Squibb Company
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Mylan N.V.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Eli Lilly and Company
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Celgene Corporation
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sanofi S.A
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Johnson & Johnson Services, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients